Drug Trial Radar · NCT04772235
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
32
Planned (sponsor's estimate)
Start
Feb 11, 2022
Primary completion
Apr 2026
Study completion Jun 2026
Sponsor
- Lead sponsor
- Instituto Oncológico Dr RosellAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Turning Point Therapeutics, Inc.
- First posted
- Feb 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I study of repotrectinib in combination with osimertinib in patients with advanced or metastatic EGFR mutant non small cell lung cancer (NSCLC). The study will be conducted in 2 parts, Part Ia and Part Ib, and its purpose will be to find the incidence of dose-limiting toxicities (DLTs) as defined by the primary safety and tolerability endpoint. The Phase Ia study will also determine the impact of repotrectinib on osimertinib pharmacokinetics (PK) and the maximum tolerated dose (MTD), if reached, of repotrectinib given in combination with osimertinib and the recommended Phase II dose (RP2D). Dose escalation will be conducted according to a 'Rolling-6' based study design with 3 dose levels for repotrectinib: 80 mg once a day (QD), 160 mg QD or 160 mf QD during 14 days followed by 160 mg twice a day (BID); in combination with 80 mg QD of osimertinib. A total of 6 patients will be enrolled in each dose level cohort. In addition, this Phase Ib study will test early drug activity (efficacy) of the proposed combination treatment in an expansion cohort at the RP2D.
Conditions
- Nsclc
Interventions
RepotrectinibDrug
Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib Part B: at the RP2D for all patients in combination with osimertinib.
OsimertinibDrug
Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted. Part B: at the RP2D level in combination with repotrectinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: Throughout the study period. Approximately 48 months
- Incidence of Dose limiting toxicities (DLTs)Time frame: During the treatment cycle 1, 21 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario Gregorio Marañón
Madrid, Spain · Recruiting
Hospital Regional Universitario de Málaga
Málaga, Andalusia, Spain · Recruiting
Hospital Son Espases
Palma, Balearic Islands, Spain · Recruiting
Quiron Dexeus
Barcelona, Catalonia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.